(ALLO) – Company Press Releases
-
Allogene Therapeutics Announces Q2 Investor Conference Participation
-
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
-
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
-
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
-
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
-
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Ventur
-
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
-
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lym
-
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
-
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
-
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
-
Allogene Therapeutics Announces Participation in December Investor Conference
-
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
-
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
-
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
-
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
-
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
-
Allogene Therapeutics Announces Participation in November Investor Conferences
-
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
-
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
-
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Allogene Therapeutics Announces Participation in September Investor Conference
-
Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.
-
Allogene Therapeutics Appoints Earl Douglas as General Counsel
-
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
-
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
-
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
-
Allogene Therapeutics Announces Departure of Chief Financial Officer
-
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
-
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
-
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
-
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
-
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
-
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
-
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
-
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
-
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
-
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
-
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
-
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
-
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
-
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
-
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
-
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
-
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
-
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Back to ALLO Stock Lookup
